Dalbavancin
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Infections
Conditions
Bacterial Infections
Trial Timeline
Apr 1, 2016 → Apr 3, 2019
NCT ID
NCT02688790About Dalbavancin
Dalbavancin is a phase 1 stage product being developed by AbbVie for Bacterial Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT02688790. Target conditions include Bacterial Infections.
What happened to similar drugs?
5 of 20 similar drugs in Bacterial Infections were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02688790 | Phase 1 | Terminated |
Competing Products
20 competing products in Bacterial Infections